Merck May Have Misrepresented Vioxx Risks The risk-benefit profile of rofecoxib (marketed under the names Vioxx,Ceoxx and Ceeoxx) may be have been misrepresented by the study sponsor,Merck, in clinical trials with patients with cognitive impairment. Thiswas the result of a comparison of internal company documents, datasubmitted by the company to the Food and Drug Administration (FDA,) andpublished clinical trial results, according to an article in the April16 issues of JAMA.
Source: www.medicalnewstoday.comSome Physicians Choosing To Stop Accepting Payments From Food, Drug, Medical Device Companies The New York Times on Tuesday profiled three research scientists who have decided to stop accepting payments from food, drug and medical device companies in response to "accusations of ethical conflicts inherent in these arrangements.
Source: www.medicalnewstoday.comUnited BioSource Acquires Leading Publication Planning Software And Services Company United BioSource Corporation (UBC) announced the acquisition of Envision Pharma, a leading scientific communications and technology company based in Horsham, UK, with offices in Southport and Glastonbury, Conn. and Philadelphia, Pa. With a focus on the pharmaceutical and biotechnology industry, Envision integrates scientific communication services and targeted software applications that contribute to marketplace awareness and comprehension of compounds at launch and beyond.
Source: www.medicalnewstoday.comNew Debate Pack Challenges Students On Hot Topics, UK The Museum of the Royal Pharmaceutical Society of Great Britain (RPSGB) is launching a Pharmacy Debate Pack, a free citizenship resource for use in secondary schools. The new resource, funded by Museums, Libraries and Archives London, encourages students to debate topical
health issues, including 'Should cannabis be legalised?' and 'Should smokers get treatment on the NHS?'.
Source: www.medicalnewstoday.comEditorials Address Increased Number Of Health Insurers Requiring Members To Pay Percentage Of Cost Of Some High-Priced Medications Two newspapers on Tuesday published editorials that address a recent New York Times article about the increased number of
health insurers that have begun to charge members a percentage of the price of certain expensive medications, rather than set copayments, to help reduce costs. Under such "Tier 4" systems, members often pay between 20% and 33% of the price of the medications, which can amount to thousands of dollars per month.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 PM
